Galapagos saw the highest growth of 3.99% in patent filings and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.24% and grants by 0.42%. GlobalData’s DataBook provides a comprehensive analysis of Galapagos‘s patent filings and grants. Buy the databook here.
Galapagos has been focused on protecting inventions in European Patent Office(EPO) with three publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 40% of filings. The European Patent Office(EPO), United States(US), Australia(AU), and Spain(ES) patent Office are among the top ten patent offices where Galapagos is filings its patents. Among the top granted patent authorities, Galapagos has 29% of its grants in United States(US), 29% in Spain(ES) and 14% in China(CN).
Roche and Johnson & Johnson could be the strongest competitors for Galapagos
Patents related to rare diseases lead Galapagos's portfolio
Galapagos has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Atopic dermatitis (atopic eczema) related patents lead Galapagos portfolio followed by psoriasis, and cardiovascular disease
Galapagos has highest number of patents in atopic dermatitis (atopic eczema) followed by psoriasis, cardiovascular disease, alopecia areata, and ileitis.
For comprehensive analysis of Galapagos's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.